The Australian Government is undertaking an independent review of the regulatory arrangements for medicines and medical devices. RANZCO’s primary concerns in response to the Expert Panel’s discussion paper relate to patient safety; timely patient access to medicines; stable supply to reduce the advent of drug shortages; appropriate red tape for use of unapproved products; and incentives for sponsors to register medicines for niche ophthalmic indications.
RANZCO’s submission is available here.